Tridoss Laboratories Private Limited
About Tridoss Laboratories Private Limited
Data last updated: 27 February 2026
Tridoss Laboratories Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Caudilo Estate Development Private Limited. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 05 October 1981, the company has been in operation for over 45 years.
Registered with ROC Mumbai under CIN U24230MH1981PTC025373.
Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹9.15 Cr. Formerly known as Tridoss Laboratories Limited and Wockhardt Laboratories Pvt Ltd. It is led by directors Nargis Akhtar Shamsi and Akhtar Fakhruddin Shamsi.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 2Nd Floor Room No 8167 Readymaoey Terrace Drannie Besant Rd Worli, Mumbai, Maharashtra, India – 400018.
As per the financials filed for FY 2025, the company reported a revenue of ₹38.05 Cr, a decline of 13% compared to the previous year.
It operates as a subsidiary of Caudilo Estate Development Private Limited. Its group structure includes 1 subsidiary.
As per MCA filings, the company has open charges of ₹17.05 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website**************
-
Social Media**************
-
Registered Address2Nd Floor Room No 8167 Readymaoey Terrace Drannie Besant Rd Worli, Mumbai, Maharashtra, India – 400018
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Tridoss Laboratories Private Limited
Tridoss Laboratories Private Limited has undergone 3 name changes throughout its history. The company was previously known as Tridoss Laboratories Limited, Wockhardt Laboratories Pvt Ltd, and Panama Laboratories Pvt Ltd. The current legal name is Tridoss Laboratories Private Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Tridoss Laboratories Private Limited | Current |
| Tridoss Laboratories Limited | Previous |
| Wockhardt Laboratories Pvt Ltd | Previous |
| Panama Laboratories Pvt Ltd | Previous |
Business Activity of Tridoss Laboratories Private Limited
Tridoss Laboratories Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Tridoss Laboratories Private Limited
Tridoss Laboratories Private Limited is audited by J.L. Thakkar & Co. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| J.L. Thakkar & Co. | blur-value | blur-value | blur-value |
Board of Directors of Tridoss Laboratories Private Limited
Tridoss Laboratories Private Limited is currently managed by 2 directors, with 3 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nargis Akhtar Shamsi | Director | 02 Sep 2002 | 23 Years 10 Months | Current |
| Akhtar Fakhruddin Shamsi | Director | 02 Sep 2002 | 23 Years 10 Months | Current |
Financials of Tridoss Laboratories Private Limited FY 2025 filings available
Tridoss Laboratories Private Limited reported revenue of ₹38.05 Cr (down 13% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Tridoss Laboratories Private Limited
As of FY 2023, Tridoss Laboratories Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Tridoss Laboratories Private Limited
Tridoss Laboratories Private Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Tridoss Laboratories Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Baruki Socks And Hosiery Private Limited | U17120MH1996PTC103652 |
**.**%
|
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Tridoss Laboratories Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Jun 1997 | Standard Chartered Bank | ₹9.5 Cr | Open |
| 22 Mar 1996 | Banque Nationale De Paris | ₹6 Cr | Open |
| 21 Jun 1993 | The British Bank of the Middle Eat | ₹1.25 Cr | Open |
| 19 Nov 1982 | Dena Bank | ₹30 Lakh | Open |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Tridoss Laboratories Private Limited
View historical data on people associated with Tridoss Laboratories Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Tridoss Laboratories Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Tridoss Laboratories Private Limited
GSTIN & GST Filing Data of Tridoss Laboratories Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Tridoss Laboratories Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Tridoss Laboratories Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Tridoss Laboratories Private Limited
MSME Payment Delays by Tridoss Laboratories Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Tridoss Laboratories Private Limited
Subsidiaries & Group Companies of Tridoss Laboratories Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Tridoss Laboratories Private Limited with ownership details.
MCA Filings & Documents of Tridoss Laboratories Private Limited
MCA Filings & Documents of Tridoss Laboratories Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Tridoss Laboratories Private Limited
Frequently Asked Questions about Tridoss Laboratories Private Limited
Tridoss Laboratories Private Limited is an active private limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 05 October 1981 (45+ years old) and is registered under CIN U24230MH1981PTC025373.
Tridoss Laboratories Private Limited reported revenue of ₹38.05 Cr for FY 2025 (down 13.00% YoY).
The current directors of Tridoss Laboratories Private Limited are:
The primary industry of Tridoss Laboratories Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Tridoss Laboratories Private Limited can be reached at the registered office: 2Nd Floor Room No 8167 Readymaoey Terrace Drannie Besant Rd Worli, Mumbai, Maharashtra, India – 400018.
The authorised capital is ₹10 Cr, and the paid-up capital is ₹9.15 Cr.